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Background. Bronchial asthma is a common disease caused by interplay between multiple determinants,
including genetic and immune variations.
Objective. To investigate the main indices of humoral and cellular branches of immunity, features of cytokine
regulation and cytokine genes in children with atopic bronchial asthma (BA) with different levels of disease
control.
Design. Fifty children with controlled BA (CBA) and 50 with uncontrolled BA (UBA) were analyzed. Mean
age in the sample was 13.3692.24 years. A control group of healthy children (n 50) was also studied. All
individuals were Russians (Eastern Slavs) from the Krasnoyarsk Territory, West Siberia. Diagnoses, severity
and level of disease control were defined according to the Global Initiative for Asthma (GINA)
recommendations. The lymphocytes were counted in blood using fluorescent microscopy. Humoral branch
indices and cytokine levels (IL-2, IL-4, IL-10 and TNF-a) in blood serum were measured by ELISA.
Genotyping of single-nucleotide polymorphism (SNP) in  590 position of the IL4 and  597 position of the
IL10 gene was performed by restriction fragment length analysis.
Results. No statistically significant differences in total IgE and cytokines blood levels were found in CBA and
UBA. However, significant differences between the groups were found for CD
3 ,C D
4  and CD
8  cell
counts. The T-590 allele of the IL4 gene, which is responsible for an increased serum level of IL-4, showed a
tendency to an association with UBA. A decreased level of IL-10 enhances control over BA, which proves its
association with the allelic variant A-597 IL10.
Conclusions. Our data show that children with UBA have higher counts of CD
3  cells and an increase of
sub-population of CD
4 -cells as well as higher levels of IgE, IL-4 and TNF-a in blood serum as com-
pared to CBA. Polymorphisms of the IL4 and IL10 genes are associated with allergic inflammation in
UBA.
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A
topic bronchial asthma (BA) is the most com-
mon disease of the respiratory tract in children
(1,2). It is characterized by repeated episodes of
bronchial obstruction due to inflammation and bronchial
hyperresponsiveness (2,3). Allergic inflammation is the
common feature of BA and other atopic diseases.
Different cytokines control the development of allergic
inflammation (4,5). Manyof them show antagonistic rela-
tionships between one another. IL-4 is the main factor
of regulation of allergic response through the control
of immunoglobulin isotype switching in B-lymphocytes
towards IgG and IgE expression (6). It also acts as a
growth factor for T-lymphocytes and mast cells and is
the key signal for the differentiation of CD
4 -cells to
T-helpers type 2 (7). These functional capabilities of IL-4
make it one of the most important cytokines for the
development of BA (4,8,9). IL4 gene is nearly 10 kb in
length and contains four exons. Several single-nucleotide
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(page number not for citation purpose)polymorphisms (SNPs) were revealed in the promoter
region of the gene (C-590T, C-285T and A-81G). The
allelic variant T-590 is associated with higher promoter
activity and increased production of IL-4 as compared
to C-590 allele (10). A polymorphism in the 3?-UTR
region of IL4 gene linked with the C-590T transition
was shown to have prognostic significance regarding BA
severity (10 12).
One of the key regulators of immune response is IL-10,
which is synthesized by activated CD
4  and CD
8  T-
lymphocytes, mast cells and activated monocytes (5,7).
IL-10 inhibits the synthesis of a range of cytokines,
produced by Th1 (IFN-g, IL-2, TNF-b, IL-1, IL-6 and
TNF-a), that leads to polarization of immune response to
the Th2-profile (13 16). In allergic patients, there is a
decrease of T-helpers producing IL-10 and low levels of
IL-10 in serum (17,18). IL10 gene is considered as a
candidate gene for BA among the other innate immunity
and immunoregulation genes (17,19). A number of SNPs
in the gene were found to be associated with the pro-
duction of IL-10 (G-1082A, C-819T, C-597A) (20). For
instance, the G allele in the  1082 position correlates
with high production of IL-10 as compared to the
alternative allele A-1082. The A-597 allele is associated
with the decrease of IL-10 production (19). The allelic
variant C-571 is associated with IgE hyperproduction
and, as a rule, with a more severe course of BA (19). It
has been shown that the G-1082A polymorphism of IL10
along with the ATA haplotype in the promoter of IL10
are associated with enhanced bronchial hyperresponsive-
ness, while the T-819C and A-592C polymorphisms as
well as the ATA and ACC haplotypes are associated with
the elevated levels of eosinophilic cationic protein in
blood serum (21,22). Meta-analysis confirmed the asso-
ciation between the G-1082A and C-597A polymorphisms
of IL10 gene and atopic BA (23).
Stable elimination of BA symptoms is called control.
Inflammatory biomarkers as well as pathophysiological
signs can be used to trace the level of disease control.
Recommendations on how to achieve BA control were
developed and summarized in the Global Initiative for
Asthma (GINA) document (2). The following goals need
to be achieved: absence or minimal manifestation of
symptoms; rare or lack of exacerbations and emergency
calls; absence of physical activity limitations; normal lung
function; minimal doses of medicines in case of emer-
gency; no side effects of treatment. The goal of BA
therapy is to achieve control over the disease by affecting
inflammation pathways. Genetic polymorphisms asso-
ciated with cytokine levels and lymphocytes counts can
be useful biomarkers of individual features of patients
which in turn can be taken into account for the adjust-
ment of therapy regimes. Extreme ecological conditions
of West Siberia result in the development of distinct
adaptive functional and metabolic characteristics of
people inhabiting the region. Immunological parameters
are one of the most sensitive markers of such adaptations.
In turn, this can cause specific patterns of BA morbidity,
clinical course and therapeutic control in the West Siberia
region. Therefore, we set out to investigate associations
between BA control, immunological traits and poly-
morphisms of IL4 and IL10 genes in children from the
city of Krasnoyarsk, West Siberia.
Materials and methods
One hundred children from Krasnoyarsk with moderate
to severe atopic BA with different disease control levels
were studied. Diagnoses, severity and the level of disease
control were defined according to recommendations of
the report of working group GINA (updated 2008) (1).
Before including a child in the study, we carried out a
baseline clinical examination, which included the esti-
mates of severity of clinical symptoms during the pre-
vious 3 months. For the enrolment to the study of the
disease control level, the children along with their parents
answered questions from the asthma control test (ACT)
which is recommended by GINA. Until the beginning of
2007, ACT was available for adults and children older
than 12 years only; however, in 2006, a younger children
version has been released. An ACT score of 20 in-
dicated controlled asthma, while an ACT score of B19
indicated uncontrolled asthma according to GINA
criteria. The results of the test in the group of the
controlled course was 22.4592.6 points, in the uncon-
trolled course, it was 14.8193.1 points (pB0.001).
The inclusion criteria for children to be part of the
research were: diagnosis of atopic BA, moderate to severe
disease course, absence of acute respiratory viral infec-
tion and other acute diseases at the time of the study,
uninterrupted combinatory basic therapy in average or
high therapeutic doses during the previous 3 months,
Russian ethnic background in 3 generations. The criteria
for healthy controls were: absence of the BA, absence of
allergic diseases in family medical records, serum level
of common IgE B100 IU/ml, Russian ethnic background
in 3 generations. Our investigation was a case control
study.
After the results of clinical examination, 3 groups were
formed: controlled BA (CBA) (n 50: 76% boys, 24%
girls), uncontrolled BA (UBA) (n 50: 70% boys, 30%
girls) and healthy control (n 50: 72% boys, 28% girls).
Mean age of children with BA was 13.3692.24 years
(M9SD). Average duration of the disease in the CBA
group was 6.1293.29 years and in UBA 8.6193.28
years. The control group of practically healthy children
had an average age of 14.890.68 years. BA patients were
enrolled in the study in the Krasnoyarsk Regional
Children’s Allergological Centre from 2009 to 2012.
The healthy children were recruited from the secondary
schools in the city of Krasnoyarsk. Informed consents
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Parameters
CBA (1)
(n 50)
UBA (2)
(n 50)
Control (3)
(n 50) p
Lymphocytes (%) 36.2911.6 30.496.7 35.795.2 p1,2 0.023
p1,3 0.0014
p2,3 0.032
p1,2,3 0.07
CD
3  (%) 51.3929.4 59.399.3 65.798.2 p1,2 0.028
p1,3 0.025
p2,3 0.028
p1,2,3 0.051
CD
3  (abs) 1467.19258.0 837.093.9 1307.29605.3 p1,2 0.014
p1,3 0.022
p2,3 0.0014
p1,2,3 0.0079
CD
4  (%) 20.6912.6 25.190.03 37.395.9 p1,2 0.007
p1,3 0.0022
p2,3 0.00046
p1,2,3 0.003
CD
4  (abs) 461.3937.9 220.6911.8 807.5927.5 p1,2 0.001
p1,3 0.014
p2,3 0.0003
p1,2,3 0.018
CD
8  (%) 38.499.7 36.197.6 25.594.9 p1,2 0.038
p1,3 0.048
p2,3 0.00023
p1,2,3 0.006
CD
8  (abs) 328.2922.4 323.9915.4 449.3915.4 p1,2 0.0075
p1,3 0.024
p2,3 0.04
p1,2,3 0.004
CD
4 /CD
8  0.6690.24 0.7590.4 1.4490.34 p1,2 0.087
p1,3 0.0006
p2,3 0.0046
p1,2,3 0.0001
IgA (g/l) 1.3990.67 1.7890.99 1.9891.96 p1,2 0.075
p1,3 0.048
p2,3 0.036
p1,2,3 0.04
IgM (g/l) 1.1890.19 1.1290.21 1.2791.03 p1,2 0.117
p1,3 0.42
p2,3 0.36
p1,2,3 0.12
IgG (g/l) 14.2294.05 13.7295.12 11.5795.21 p1,2 0.113
p1,3 0.06
p2,3 0.11
p1,2,3 0.062
IgE (IU/ml) 227.95924.62 359.61931.22 71.56913.43 p1,2 0.057
p1,3B0.001
p2,3B0.001
p1,2,3 0.032
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parents. The protocol of the study was approved by the
Ethical Committee of the Research Institute for Medical
Problems of the North.
Specific allergological examination included the collec-
tion of relevant medical history, skin-prick tests for
domestic, epidermal and pollen allergens. Respiration
function was measured by spirometry and pickflouro-
metric test for reversibility of bronchial obstruction.
Peripheral blood was collected from fasting partici-
pants in the morning. Cytokine concentration in blood
serum (IL-2, IL-4, IL-10 and TNF-a) was determined
by ELISA (Vector-Best, Novosibirsk, Russia). DNA was
isolated from 100-ml EDTA blood using Medigen DNA
purification kit (MEDIGEN Laboratory, Novosibirsk,
Russia).
Two polymorphisms in promoter regions of the
cytokines genes were analyzed (C-590T IL4 and C-597A
IL10) in a subset of 31 children from CBA group and 33
children for UBA group. Genotyping was performed by
polymerase chain reaction (PCR) followed by restric-
tion endonuclease cleavage. PCR was carried out using
primers described earlier (24 26).
Statistical analysis was performed using Statistica for
Windows 6.0. Non-parametric Mann Whitney U-test
was applied to compare mean values of quantitative
traits. Genotype frequencies were tested for deviation
from Hardy-Weinberg equilibrium (HWE) by Fisher’s
exact test.
Results
The study for parameters of immune status showed the
statistically significant peculiarities of immune reactivity
associated with the level of disease control (Table I).
In CBA, increased levels of total lymphocyte counts,
absolute counts of CD
3  cells and percentage of CD
8 -
lymphocytes in comparison with control were found.
In the UBA group, as compared to the control, we
revealed a statistically significant decrease in total lym-
phocyte counts, mature T-lymphocytes and CD4
  T-
lymphocytes as well as a decrease in the immune
regulatory index (CD
4 /CD
8 ). However, the levels of
CD
8  T-lymphocytes turned out to be evidently higher in
UBA compared to the control. The differences between
CBA and UBA were not pronounced, but were statisti-
cally significant.
The analysis of the humoral branch of immunity
showed a significant decrease of IgA levels in both
groups of BA as compared with the control (Table I).
In the CBA group, we found an increase of IgG
Table II. Concentration of cytokines in blood serum in patients with BA with different levels of control over disease (Me (Q25 Q75))
No. Group name IL-2 (pg/ml) IL-4 (pg/ml) IL-10 (pg/ml) TNF-a (pg/ml)
1 CBA (1)
(n 50)
24.06
(7.96 38.43)
5.27
(2.85 7.82)
36.52
(20.51 48.72)
16.61
(15.29 29.52)
2 UBA (2)
(n 50)
11.81
(8.53 30.57)
5.83
(3.79 14.83)
37.39
(21.73 42.63)
25.62
(18.62 31.48)
3 Control (3)
(n 50)
5.23
(2.44 7.20)
2.45
(0.84 4.99)
15.89
(6.74 27.83)
6.63
(2.58 11.87)
4P p 1,2 0.84
p1,3 0.006
p2,3 0.005
p1,2 0.48
p1,3 0.0019
p2,3B0.001
p1,2 0.98
p1,3B0.001
p2,3B0.001
p1,2 0.006
p1,3B0.001
p2,3B0.001
Table III. Prevalence of the -590 IL4 and -597 IL10 genotypes in studied groups (%)
IL4 C-590T
Control (1)
(n 50)
ABA (2)
(n 64)
CBA (3)
(n 31)
UBA (4)
(n 33) OR CI p
CC
CT
TT
59.6
38.5
1.9
56.2
39.1
4.7
61.3
35.5
3.2
51.5
42.4
6.1
OR1,2 0.87
OR1,3 1.07
OR1,4 1.19
OR3,4 1.49
CI1,2 0.39 1.9
CI1,3 0.39 2.9
CI1,4 0.76 1.5
CI3,4 0.49 4.5
p1,2 0.71
p1,3 0.83
p1,4 0.74
p3,4 0.43
IL10 C-597A OR CI p
CC
CA
AA
73.1
26.9
0
62.5
29.7
7.8
61.3
29.0
9.7
63.6
30.3
6.1
OR1,2 1.88
OR1,3 2.05
OR1,4 1.73
OR3,4 0.84
CI1,2 0.89 4.2
CI1,3 0.85 4.1
CI1,4 0.86 4.2
CI3,4 0.34 2.1
p1,2 0.07
p1,3 0.08
p1,4 0.18
p3,4 0.68
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control (p 0.06). The concentration of total IgE was
statistically significantly higher in CBA and UBA groups
compared to the control. Notably, the level of IgE was
higher in UBA than in CBA (p 0.057).
The analysis of cytokine levels revealed a statistically
significant increase of Th1-cytokines (IL-2, TNF-a) and
Th2-cytokines (IL-4, IL-10) both in CBA and UBA
groups as compared to the control (Table II). The Th2-
cytokine levels in the UBA group were higher than in
CBA. However, the differences were not statistically
significant. In children with BA, the significant increase
in TNF-a was observed. Also, the level of TNF-a in UBA
was statistically significantly higher than in CBA (0.006).
The study of C-590T IL4 polymorphism showed the
high incidence of the CC homozygote variant (56.2% in
BA and 59.6% in control). The prevalence of the mutant
variant genotype TT was minimal in the control group
and more common in affected children (1.9 and 4.7%,
respectively; p 0.015) (Table III).
The  597AA genotype of IL10 gene was not found in
the control group. Simultaneously, its prevalence in CBA
was 9.7% (p 0.08). We showed the trend for correla-
tion between the A-597 allele variant with a decreased
Table IV. The level of the IL-4 and IL-10 in individuals with different genotypes of the IL4 and IL10 genes (pg/ml)
CBA (1) (n 31) UBA (2) (n 33) Control (3) (n 50)
IL4
C-590T
IL-4
Me (Q25 Q75)
IL4
C-590T
IL-4
Me (Q25 Q75)
IL4
C-590T
IL-4
Me (Q25 Q75)p
C/C (n 19) 5.6
(2.8 7.9)
C/C (n 17) 5.1
(3.7 14.0)
C/C (n 39) 2.0
(1.3 2.1)
p1,2 0.018
p1,3 0.013
p2,3 0.082
C/T (n 12) 4.6
(3.3 6.1)
C/T (n 16) 8.3
(3.9 15.1)
C/T (n 11) 3.4
(2.4 4.4)
p1.2 0.056
p1.3 0.031
p2.3 0.24
p 0.48 p 0.5 p 0.07
IL10 C-597A IL-10
Me (Q25 Q75)
IL10
C-597A
IL-10
Me (Q25 Q75)
IL10
C-597A
IL-10
Me (Q25 Q75)
C/C (n  19) 34.8
(21.3 51.3)
C/C (n 21) 39.1
(24.4 42.6)
C/C (n 42) 16.3
(9.6 20.7)
p1.2 0.0043
p1.3 0.003
p2.3 0.001
C/A (n 12) 39.6
(18.8 46.5)
C/A (n 12) 33.5
(19.8 39.6)
C/A (n 8) 13.9
(13.4 14.4)
p1.2 0.075
p1.3 0.019
p2.3 0.008
p 0.66 p 0.17 p 0.64
Table V. The levels of the cytokines in individuals with different genotypes of the IL4 and IL10 genes (pg/ml)
BA (n 64) Control (n 50) p
IL4 C-590T IL-4
Me (Q25 Q75)
IL4
C-590T
IL-4
Me (Q25 Q75)
C/C (n 36) 5.2
(2.9 14.0)
C/C (n 39) 2.0
(1.3 2.1)
0.0006
C/T (n 28) 7.7
(4.1 15.1)
C/T (n 11) 3.4
(2.4 4.4)
0.012
p 0.065 p 0.07
IL10 C-597A IL-10
Me (Q25 Q75)
IL10
C-597A
IL-10
Me (Q25 Q75)
C/C (n 40) 37.7
(21.3 42.6)
C/C (n 42) 16.3
(9.6 20.7)
0.05
C/A (n 24) 36.4
(8.8 19.8)
C/A (n 8) 13.9
(13.4 14.4)
0.018
p 0.28 p 0.65
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A-597 variant of IL10 in the BA group was higher than in
the control group, though the difference did not reach
statistical significance (p 0.074; OR: 1.88; CI: 0.89 4.1).
The levels of serum IL-4 in CBA and UBA groups as
well as the level of IL-4 in the control group among the
individuals with  590CC and  590CT genotypes of
IL4 gene were not significantly different. However, there
was a trend towards an increase of the IL-4 serum levels
in healthy carriers with  590CT genotype as compared
to  590CC (3.4 and 2.0 pg/ml, respectively; p 0.07).
No significant differences in serum levels of IL-10 among
individuals with  597CC and  597CA genotypes of
IL10 were observed in the analyzed groups (Table IV).
Median levels of IL-4 in BA children with IL4
 590CC genotype were 5.2 pg/ml (Q25 Q75 range:
2.9 14.0), while in the control group they were 2.0 pg/
ml (1.3 2.1) (p 0.0006) (Table V and Figure 1). In
carriers with genotype CT in these groups, median levels
of IL-4 were to 7.7 pg/ml (4.1 15.1) and 3.4 (2.4 4.4),
respectively (p 0.012). Within the groups, in carriers
with different genotypes (CC and CT), and also in CBA
and UBA, the levels of IL-4 did not significantly differ.
Median levels of serum IL-10 in BA children with IL10
CC-597 genotype were 37.7 pg/ml (21.3 42.6), while
in the control group they were 16.3 pg/ml (9.6 20.7)
(p 0.05). In CBA and UBA groups, in carriers of CC
genotype, we revealed statistically significant differences
in IL-10 levels (p 0.0043). In BA carriers with CA
genotype, the levels of IL-10 were 36.4 pg/ml (8.8 19.8),
while in the control group they were 13.9 (13.4 14.4)
(p 0.018).
Conclusion
The analysis of clinical, immunologic and genetic traits
revealed specific features of uncontrolled course of BA in
children from Krasnoyarsk region.
The parameters of immune status in children with UBA
are characterized by T-lymphocytes deficiency, lower
counts of CD
4  cells and lower CD
4 /CD
8  ratio. The
humoral branch of immunity expresses disimmunoglobu-
linemia, namely, the decrease in IgA production and over-
production of IgE both in CBA and UBA groups as
compared with the control. The revealed changes of
humoral and cellular branches of immunity in children
with BAwith different levels of the disease control reflect
specific features of atopy, such as IgE hyperproduction
and T-lymphocyte deficiency, including Th-cells, as com-
pared with the control group. It was shown that IgE
deficiency due to persistent inflammation is most pro-
nounced in cases of atopic BA with low disease control
level.
The character of changes in the levels of cytokines
in blood serum can be considered as a biomarker of
uncontrolled course of atopic BA in children. This is
based on the assumption that co-activation occurs in
both Th1- and Th2-lymphocytes, as confirmed by high
levels of cytokines TNF-a and IL-4.
It was shown that the IL4 T-590 allele causes
hyperproduction of IL-4 and tends to associate with an
uncontrolled course of atopic BA due to IL-4 effects as
the main modulator of allergic inflammation. The IL10
A-597 allele is associated with low expression of IL-10
and influences the level of control over the course of
atopic BA in children, preventing the deviation of
immune response towards Th2 profile.
Under-diagnosis of BA among children is currently
common worldwide leading to the development of severe
uncontrolled forms of the disease course. Our study
revealed clinical, immunological and genetic particula-
rities of UBA in children from the Krasnoyarsk region;
the data can be used as a reference to compare with
children from other regions.
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